GenixCure

SCROLL

AAV Capsid Engineering

CARE™ explores novel AAV vectors with improved on-target specificity offering clinical safety.

For patients and clinicians fighting for rare genetic diseases

We design and serve plasmids, vectors,
and viruses for AAV
gene therapy programs from researchers
to bio-pharmas around the world.

Business

Meet the demands of organization-specific AAV capsid with CARE™

Business

Genixcure develops therapeutic programs for CNS & genetic rare diseases

Business

	Candidate	Indication	Development status
			Research Lead Optimization	In Vitro In Vivo	Phase Ⅰ Phase Ⅱ Phase Ⅲ	NDA Commercialization
			Rare Genetic Disease	GXC-301	Lafora disease	In Vivo ODD & RPDD granted by US FDA
GXC-302	Undisclosed	In Vitro
GXC-303	ALS	In Vivo
GXC-304	Fronto Temporal Dementia	In Vivo